Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation

doi:10.1038/s41408-021-00437-z

. 2021 Mar 4;11(3):49.

doi: 10.1038/s41408-021-00437-z.

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation

Maansi Joshi^#¹, Joselle Cook^#¹, Kristen McCullough¹, Ahmad Nanaa¹, Naseema Gangat¹, James M Foran², Hemant S Murthy², Mohamed A Kharfan-Dabaja², Lisa Sproat³, Jeanne Palmer³, Animesh Pardanani¹, Ayalew Tefferi¹, Kebede Begna¹, Michelle Elliot¹, Aref Al-Kali¹, Mrinal Patnaik¹, Mithun V Shah¹, William J Hogan¹, Mark R Litzow¹, Hassan B Alkhateeb⁴

Affiliations

¹ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
² Division of Hematology & Medical Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA.
³ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA.
⁴ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. alkhateeb.hassan@mayo.edu.

^# Contributed equally.

PMID: 33664234
PMCID: PMC7933161
DOI: 10.1038/s41408-021-00437-z

Free PMC article

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation

Maansi Joshi et al. Blood Cancer J. 2021.

Free PMC article

. 2021 Mar 4;11(3):49.

doi: 10.1038/s41408-021-00437-z.

Authors

Affiliations

¹ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
² Division of Hematology & Medical Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA.
³ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA.
⁴ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. alkhateeb.hassan@mayo.edu.

^# Contributed equally.

PMID: 33664234
PMCID: PMC7933161
DOI: 10.1038/s41408-021-00437-z

No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. Al-Kali reports institutional research support by Celgene and Dr. Litzow reports research support by AbbVie. In addition, Dr. Kharfan-Dabaja discloses consultancy for Daiichi Sankyo Company and Pharmacyclics. No other authors report any conflicts of interests.

Figures

**Fig. 1. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic stem cell transplant.**
A Overall survival and B leukemia-free survival in responders vs non-responders in patients receiving VEN for post-transplant relapse.

See this image and copyright information in PMC

Cited by

Successful Treatment With Venetoclax Plus Azacytidine Combined With Radiation Therapy and Donor Lymphocyte Infusion in a Patient With Extramedullary Relapse of Acute Myeloid Leukemia After Stem Cell Transplantation.
Shirato S, Iyama S, Fujimi A, Takahashi S, Kobune M. Shirato S, et al. Cureus. 2024 Feb 5;16(2):e53655. doi: 10.7759/cureus.53655. eCollection 2024 Feb. Cureus. 2024. PMID: 38449958 Free PMC article.
Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia.
Fan R, Satilmis H, Vandewalle N, Verheye E, De Bruyne E, Menu E, De Beule N, De Becker A, Ates G, Massie A, Kerre T, Törngren M, Eriksson H, Vanderkerken K, Breckpot K, Maes K, De Veirman K. Fan R, et al. Blood Cancer J. 2023 Dec 18;13(1):188. doi: 10.1038/s41408-023-00962-z. Blood Cancer J. 2023. PMID: 38110349 Free PMC article.
LAIR-1 agonism as a therapy for acute myeloid leukemia.
Lovewell RR, Hong J, Kundu S, Fielder CM, Hu Q, Kim KW, Ramsey HE, Gorska AE, Fuller LS, Tian L, Kothari P, Paucarmayta A, Mason EF, Meza I, Manzanarez Y, Bosiacki J, Maloveste K, Mitchell N, Barbu EA, Morawski A, Maloveste S, Cusumano Z, Patel SJ, Savona MR, Langermann S, Myint H, Flies DB, Kim TK. Lovewell RR, et al. J Clin Invest. 2023 Nov 15;133(22):e169519. doi: 10.1172/JCI169519. J Clin Invest. 2023. PMID: 37966113 Free PMC article.
Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation.
Liberatore C, Di Ianni M. Liberatore C, et al. Int J Mol Sci. 2023 Oct 9;24(19):15019. doi: 10.3390/ijms241915019. Int J Mol Sci. 2023. PMID: 37834466 Free PMC article. Review.
Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Du Y, Li C, Zhao Z, Liu Y, Zhang C, Yan J. Du Y, et al. BMC Cancer. 2023 Aug 17;23(1):764. doi: 10.1186/s12885-023-11259-6. BMC Cancer. 2023. PMID: 37592239 Free PMC article.

See all "Cited by" articles

References

1. Bejanyan N, et al. Survival of AML patients relapsing after allogeneic hematopoietic cell transplantation: a CIBMTR study. Biol. Blood Marrow Transpl. 2015;21:454–459. doi: 10.1016/j.bbmt.2014.11.007. - DOI - PMC - PubMed
1. Pollyea DA, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat. Med. 2018;24:1859–1866. doi: 10.1038/s41591-018-0233-1. - DOI - PMC - PubMed
1. DiNardo CD, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17. doi: 10.1182/blood-2018-08-868752. - DOI - PMC - PubMed
1. DiNardo, C. et al. A randomized, double-blinded, placebo-controlled study of venetoclax with azacitidine vs azacitidine in treatment-naive patients with acute myeloid leukemia ineligible for intensive therapy-viale-A. EHA Haematol. LB2601, (2020).
1. Dombret H, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291–299. doi: 10.1182/blood-2015-01-621664. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- Genetic Alliance
- MedlinePlus Health Information

[1] Bejanyan N, et al. Survival of AML patients relapsing after allogeneic hematopoietic cell transplantation: a CIBMTR study. Biol. Blood Marrow Transpl. 2015;21:454–459. doi: 10.1016/j.bbmt.2014.11.007. - DOI - PMC - PubMed

[2] Bejanyan N, et al. Survival of AML patients relapsing after allogeneic hematopoietic cell transplantation: a CIBMTR study. Biol. Blood Marrow Transpl. 2015;21:454–459. doi: 10.1016/j.bbmt.2014.11.007. - DOI - PMC - PubMed

[3] Pollyea DA, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat. Med. 2018;24:1859–1866. doi: 10.1038/s41591-018-0233-1. - DOI - PMC - PubMed

[4] Pollyea DA, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat. Med. 2018;24:1859–1866. doi: 10.1038/s41591-018-0233-1. - DOI - PMC - PubMed

[5] DiNardo CD, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17. doi: 10.1182/blood-2018-08-868752. - DOI - PMC - PubMed

[6] DiNardo CD, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17. doi: 10.1182/blood-2018-08-868752. - DOI - PMC - PubMed

[7] DiNardo, C. et al. A randomized, double-blinded, placebo-controlled study of venetoclax with azacitidine vs azacitidine in treatment-naive patients with acute myeloid leukemia ineligible for intensive therapy-viale-A. EHA Haematol. LB2601, (2020).

[8] DiNardo, C. et al. A randomized, double-blinded, placebo-controlled study of venetoclax with azacitidine vs azacitidine in treatment-naive patients with acute myeloid leukemia ineligible for intensive therapy-viale-A. EHA Haematol. LB2601, (2020).

[9] Dombret H, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291–299. doi: 10.1182/blood-2015-01-621664. - DOI - PMC - PubMed

[10] Dombret H, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291–299. doi: 10.1182/blood-2015-01-621664. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation

Affiliations

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation

Authors

Affiliations

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical